Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06336005
PHASE1

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in participants body, and what the body does to the study medicine. Participants will either get NNC6022-0001 (the new study medicine) or placebo (a "dummy medicine" without the active ingredient). Which treatment participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors. The study will last for about 10 months in total.

Official title: A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

56

Start Date

2024-03-28

Completion Date

2025-02-17

Last Updated

2026-06-30

Healthy Volunteers

Yes

Interventions

DRUG

NNC6022-0001

Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.

DRUG

Placebo (NNC6022-0001)

Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts

Locations (1)

ICON - location Groningen

Groningen, Netherlands